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and Sergio Marangoni1
A new crotoxin B isoform PLA2 (F6a), from Crotalus durissus collilineatus was puriﬁed from
by one step reverse phase HPLC chromatography using l-Bondapack C-18 column analytic.
The new crotoxin B isoform PLA2 (F6a), complex crotoxin, the catalytic subunit crotoxin B
isoform PLA2 (F6a) and two crotapotin isoforms (F3 and F4), were isolated from the venom
of Crotalus durissus collilineatus. The crotapotins isoforms F3 and F4 had similar chemical
properties, the two proteins diﬀerent in their ability to inhibit of isoforms of PLA2 (F6 and
F6a). The molecular masses estimated by MALDI-TOF mass spectrometry were: crotoxin B:
14,943.14 Da, crotapotin F3: 8,693.24 Da, and crotapotin F4: 9 314.56 Da. The new crotoxin
B isoform PLA2 (F6a) contained 122 amino acid residues and a pI of 8.58. Its amino acid
sequence presents high identity with those of other PLA2s, particularly in the calcium binding
loop and active site helix 3. It also presents similarities in the C-terminal region with other
myotoxic PLA2s. The new crotoxin B isoform PLA2 (F6a) contained 122 amino acid residues,
with a primary structure of HLLQFNKMIK FETRRNAIPP YAFYGCYCGW
GGRGRPKDAT DRCCFVHDCC YGKLAKCNTK WDFYRYSLKS GYITCGKGTW
CEEQICECDR VAAECLRRSL STYRYGYMIY PDSRCRGPSE TC. A neuromuscular
blocking activity was induced by crotoxin and new crotoxin B isoform PLA2 (F6a) in the
isolated mouse phrenic nerve diaphragm and the biventer cervicis chick nerve-muscle
preparation. Whole crotoxin was devoid of cytolytic activity upon myoblasts and myotubes in
vitro, whereas new crotoxin B isoform PLA2 (F6a) was clearly cytotoxic to these cells.
KEY WORDS: Biventer cervicis chick; Crotalus durissus collilineatus; crotoxin; crotoxin B isoform PLA2
(F6a); mass spectrometry Maldi-Tof; myoblasts; myotubes; venom; neurotoxin.
1. INTRODUCTION
In Brazil, bites by subspecies of the rattlesnake Cro-
talus durissus are responsible for 7–8% of the bites
by venomous snakes reported annually in this coun-
try (Arau´jo, 2003). Envenoming by these snakes is
characterized by neurotoxicity, systemic myotoxicity,
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spectral proﬁles, mass spectrometric spectral proﬁles.
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edema and acute renal failure (Azevedo-Marques,
1982).
Crotoxin is a potent neurotoxic and myotoxic
heterodimeric phospholipase A2 (PLA2) present in
high concentration in the venom of various South
American subspecies of the rattlesnake Crotalus du-
rissus (Lennon and Kaiser, 1990; Beghini, 2000;
Ponce-Soto, 2002; Rangel-Santos, 2004). Crotoxin
exists in several isoforms, which vary in their bio-
logical activity, probably as a result of the heteroge-
neity in the PLA2 and crotapotins (Faure and Bon,
1987). The multiplicity and diversity of crotoxin iso-
forms may be due to post-translational modiﬁcation
of a unique precursor of crotoxin or from the
expression of diﬀerent mRNAs (Faure and Bon,
1987, 1988; Faure, 1991, 1993, 1994; Oliveira,
2002).
Snake venom PLA2s displays a variety of
activities, such as neurotoxicity, myotoxicity, car-
diotoxicity and hemolysis that may be modulated
by speciﬁc receptors located on target cells (Kini
and Evans, 1989; Gutie´rrez and Ownby, 2003;
Kini, 2003). Indeed, PLA2 receptors classiﬁed as
types M and N (Lambeau and Lazdunski, 1999)
have been identiﬁed in various types of cells.
Snake venom PLA2 can bind to M receptors,
which are the most common type found in
human macrophages and muscle cells, and these
may mediate some of the deleterious actions of
venom PLA2s, although this remains to be con-
clusively demonstrated (Gutie´rrez and Ownby,
2003).
Crotalus durissus collilineatus is a clinically
important rattlesnake species found in central Bra-
zil, but there have been few studies of its venom
and its main toxin a crotoxin homolog. The ab-
sence of crotamine in Crotalus durissus collilineatus
venoms collected in the States of Goias and Mato
Grosso (central Brazil) is particularly interesting
since this toxin has myotoxin and neurotoxin
activities and accounts for 20% of the dry venom
neight. These ﬁndings suggested that the crotoxin
isoforms from Crotalus durissus collilineatus proba-
bly plays an important role in this venoms action
(Ponce-Soto, 2002). Several studies have shown
that the venom of Crotalus durissus terriﬁcus con-
tains various isoforms of PLA2 (Faure and Bon,
1987, 1988; Faure, 1991, 1993, 1994). In this
work, we describe the biochemical and pharmaco-
logical characterization of a new crotoxin B iso-
form PLA2 (F6a) of crotoxin B from Crotalus
durissus collilineatus.
2. MATERIALS AND METHODS
2.1. Venom, Chemicals and Reagents
Dessicated Crotalus durissus collilineatus venom
was purchased from a private serpentarium (Batatais,
SP, Brazil). All chemicals and reagents used in this
work were of analytical or sequencing grade.
2.2. Animals
Male HY-LINE W36 chickens (4–8 days old)
were kindly supplied by Granja Ito S/A (Sumare´,
SP, Brazil). Animals had free access to food and
water. The Animal Services Unit of the State Uni-
versity of Campinas (UNICAMP) supplied male
Swiss white mice (26–32 g). The mice were housed
at 25 C on a 12 h light/dark cycle and had free ac-
cess to food and water.
2.3. Isolation and Puriﬁcation of New PLA2 Isoform
F6a in Reverse Phase HPLC (RP-HPLC)
Twenty milligrams of the whole venom of Cro-
talus durissus collilineatus were dissolved in 250 ll
of 0.1% (v/v) triﬂuoroacetic acid (solvent A) and
the resulting solution was clariﬁed by centrifugation
prior to loading the supernatant onto a l-Bonda-
pack C-18 column (0.78 cm 30 cm; Waters 991-
PDA system). Proteins were eluted with a linear
gradient (0–100%) of 66.5% (v/v) acetonitrile in
0.1% (v/v) triﬂuoroacetic acid (solvent B), at a ﬂow
rate of 2.0 ml/min. The elution proﬁle was moni-
tored at 280 nm and fractions were manually col-
lected, lyophilized and stored at )20C. The
puriﬁed proteins obtained were referred as F6 and
F6a.
2.4. PLA2 Activity.
PLA2 activity was measured using the assay de-
scribed (Cho and Ke´zdy, 1991) and (Holzer and
Mackessy, 1996), modiﬁed for 96-well plates (Ponce-
Soto, 2002). The standard assay mixture contained
200 ll of buﬀer (10 mM Tris–HCl, 10 mM CaCl2,
100 mM NaCl, pH 8.0), 20 ll of substrate (4-nitro-
3-octanoyloxy-benzoic acid), 20 ll of water and
20 ll of PLA2 in a ﬁnal volume of 260 ll. After the
addition of PLA2 (20 lg), the mixture was incubated
for up to 40 min at 37 C, with the absorbance
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being read at 10 min intervals. The enzyme activity,
expressed as the initial velocity of the reaction (Vo)
was calculated based on the increase in absorbance
after 20 min. The inhibition of PLA2 activity by
crotapotin was determined by co-incubating both
proteins for 30 min at 37 C and then assaying the
residual enzyme activity. All assays were conducted
in triplicate, and the absorbances at 425 nm were
measured using a SpectraMax 340 multiwell plate
reader (Molecular Devices).
2.5. Amino Acid Analysis
Amino acid analysis was performed on a Pico-
Tag amino acid analyzer (Water System) as described
elsewhere (Henrikson and Meredith, 1984). One
nanomole of PLA2 or isoforms of crotapotins was
hydrolyzed in 6 M HCL/1% phenol at 106 C for
24 h. The hydrolysates were reacted with 20 lL of
fresh derivatization solution (methanol:triethyl-
amine:water:phenylisothiocyanate, 7:1:1:1, v/v) for
1 h at room temperature. After pre-column derivati-
zation, PTC amino acids were identiﬁed on a reverse
phase HPLC-column by comparing their retention
times to those of standard PTC-amino acids (Pierce).
Cysteine residues were quantiﬁed as cysteic acid.
2.6. Reduction and Carboxymethylation of Protein
and Digestion of New PLA2 Isoform F6a
One milligram of puriﬁed PLA2 F6a isoform
was dissolved in 6 M guanidine chloride (Merck)
containing 0.4 M Tris–HCl and 2 mM EDTA (pH
8.1); this was reduced with DTT and then carbo-
xymethylated with 14C iodoacetic acid (Ponce-Soto,
2006). Desalting was performed on a Sephadex
G-25 column in 1 M acetic acid at 25 C, and the
modiﬁed protein (RC-F6a) was lyophilized. The
reduced and carboxymethylated protein was digested
with Staphylococcus aureus protease SV8 for 17 h at
37 C using a 1:30 enzyme-to-substrate molar ratio;
the reaction was stopped by lyophilization. The
RC-F6a was also digested with Clostripain for 8 hr
at 37 C and then lyophilized again. The digested
products of this treatment were fractionated by
reverse-phase HPLC using a Waters PDA 991 sys-
tem and a C18 l-Bondapack column. The elution
of peptide peaks was made using a linear gradient
consisting of 0–100% of acetonitrile in 0.1% triﬂuo-
roacetic acid (v/v).
2.7. Sequencing procedure
The sequencing of the N-terminal of new cro-
toxin B isoform PLA2 F6a, was conducted for the
reduced and carboxymethylated protein, and the
sequencing of peptide peaks in re-puriﬁed digest in
products was performed using a Procise automatic
sequencer (Applied). Peptides containing 14C-CM-
Cys were monitored by detecting radioactivity with
the use of a liquid scintillation counter (Beckman
model L-250).
2.8. Maldi-Tof Mass Spectrometric Analysis (MS)
The molecular mass of new crotoxin B isoform
PLA2 F6a and isoforms of crotapotins (F3 and F4)
were analyzed by MALDI-TOF mass spectrometry
using a Voyager-DE PRO MALDI-TOF mass spec-
trometer (Applied Biosystems, Foster City, CA,
USA). 1 lL. of sample on TFA 0.1% were mixed
with 2 lL. of the matrix. For the crotapotin
isoforms we used a-cyano-4-hydroxycinnamic acid
(a-Cyano, CHCA) 50% acetonitrile, 0.1% TFA v/v
and phospholipase A2 (F6); sinapinic acid (3,5-di-
methoxy-4-hydroxycinnamic acid). The matrix was
prepared with 30% acetonitrile and 0.1% v/v TFA
and their mass analyzed under the following condi-
tions: accelerate voltage 25 kV, the laser ﬁxed in
2890 lJ/com2, delay 300 ns and in linear analysis
mode (Smolka, 2001).
2.9. Mouse Phrenic Nerve-Diaphragm Muscle
Preparation
The phrenic nerve and diaphragm (Bulbring,
1946) were obtained from mice anesthetized with
chloral hydrate (300 mg/kg, i.p.) and sacriﬁced by
exsaguination. The diaphragm was removed and
mounted under a tension of 5 g in a 5 ml organ
bath containing Tyrode solution (pH 7.4, 37 C)
of the following composition (mM): NaCl 137,
KCl 2.7, CaCl2 1.8, MgCl2 0.49, NaH2PO4 0.42,
NaHCO3 11.9 and glucose 11.1, aerated with 95%
O2 and 5% CO2. Supramaximal stimuli
(4 threshold, 0.1 Hz, 0.2 ms) delivered from a
Grass S48 stimulator (Astro-Med, Inc., W. War-
wick, RI) were applied to the nerve through bipo-
lar electrodes. Isometric muscle tension was
recorded by a force displacement transducer (Load
Cell BG-10 GM, Kulite Semiconductor Products,
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Inc., NJ) coupled to a physiograph (Gould, Model
RS 3400) via a Gould universal ampliﬁer (both
from Gould, Inc., Recording Systems Division,
Cleveland, OH).
The preparations were allowed to stabilize for
at least 10 min before the addition of crotoxin and
new crotoxin B isoform PLA2 F6a from Crotalus
durissus collilineatus venom (10 lg/ml).
2.10. Eﬀects on the Chick Biventer Cervicis
Preparation
The biventer cervicis was removed as previously
described by (Ginsborg and Warriner, 1960)
and mounted under a tension of 1 g in a 5 ml
organ bath containing Krebs solution (pH 7.5,
37 C) of the following composition (mM): NaCl,
118,6; KCl, 4.69; CaCl2, 1.88; KH2PO4, 1.17;
MgSO4, 1.17; NaHCO3, 25.0; C6H12O6 11.65. The
solution was bubbled with oxygen containing 5%
CO2. Stimuli (0.1 Hz, 0.2 ms, supramaximal stim-
uli, 4 threshold) from a Grass S4 stimulator
were delivered to the tendon through bipolar elec-
trodes. Thresholding muscle tension was recorded
isometrically by a force-displacementtransducer
(BG 25 GM Kulite) coupled to a Gould RS 3400
recorder. The preparation was allowed to stabilize
for at least 15 min before the addition of a single
dose of venom or isolated crotoxin. Contractures
to exogenously applied submaximal concentrations
of acetylcholine (14.6 mM for 60 s) and KCl
(13.3 mM for 120–130 s) were obtained in the ab-
sence of nerve stimulation prior to and after the
addition of the venom, as an assay for neurotoxic
activity (Harvey, 1994).
2.11. Cytotoxic Activity
Cytotoxic activity was assayed on murine
skeletal muscle C2C12 myoblasts and myotubes
(ATCC CRL-1772) as described (Lomonte, 1999).
Variable amounts of toxin were diluted in assay
medium (Dulbeccos Modiﬁed Eagles Medium
supplemented with 1% fetal calf serum) and
added to cells in 96-well plates, in 150 ll. Controls
for 0 and 100% toxicity consisted of assay med-
ium, and 0.1% Triton X-100, respectively. After
3 h at 37 C, a supernatant aliquot was collected
for determination of lactic dehydrogenase (LDH;
EC 1.1.1.27) activity released from damaged cells,
using a kinetic assay (Wiener LDH-P UV).
Experiments were carried out in triplicate.
2.12. Statistical Analysis
The results are reported as the means±SEM
of n experiments, as appropriate. The signiﬁcance of
diﬀerences between means was assessed by analysis
of variance followed by Dunnetts test when several
experimental groups were compared with the control
group. The conﬁdence limit for signiﬁcance was 5%.
3. RESULTS
3.1. Puriﬁcation of New Crotoxin B Isoform PLA2
F6a
Fractionation of Crotalus durissus collilineatus
venom by reverse-phase HPLC (Fig. 1a) showed the
elution of eight main fractions: F2, F3 and F4 were
identiﬁed as crotapotins isoforms, F6 and F6a
exhibited PLA2 activity and F101 were identiﬁed as
protease, Cvx identiﬁed convulxin and Gyr as
gyroxin, respectively.
3.2. Activity Measurements of New Crotoxin B
Isoform PLA2 F6a
The PLA2 activity of new crotoxin B isoform
PLA2 F6a, were studied using the synthetic chro-
mogenic substrate 4-nitro-3-(octanoyloxy) benzoic
acid.
The PLA2 activity of whole venom from Crota-
lus durissus collilineatus was 1.423±0.08 nmol/min,
crotoxin was 2.01±0.10 nmol/min, crotoxin B (F6)
9.87±0.31 nmol/min and new crotoxin B isoform
PLA2 F6a, was 9.78±0.265 nmol/min (Fig. 1b).
The crotapotins isoforms F3 and F4 inhibited
crotoxin B (F6) and new crotoxin B isoform PLA2
(F6a), activity. The crotoxin B (F6) was the least
sensitive to inhibition by the crotapotin isoforms
isolated here (Fig. 1b).
3.3. Amino Acid Analysis
The amino acid composition of new crotoxin B
isoform PLA2 F6a showed a high content of basic
amino acids (Arg, Lys) and hydrophobic amino
acid residues (Gly, Ala). The presence of 14 half-
cysteines residues suggests the presence of seven
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disulﬁde bridges. The crotapotins F3 and F4
showed a high content of acid amino acids (Asx,
Glx) and diﬀered in their content of Ala and Pro,
with F3 being slightly less hydrophobic than
isoform F4 (Fig. 2a).
3.4. Maldi-Tof Mass Spectrometric Analysis
The MS spectral proﬁles of the crotoxin
obtained by reverse-phase HPLC and phospholipase
A2 new crotoxin B isoform F6a, and the isoforms
of crotapotins (F3, F4) obtained by HPLC-FR are
shown in Fig. 2b. The MS spectral data for iso-
forms of crotapotins F3, F4 were 8693.25 and
9341.56 Da, respectively. The PLA2 (F6) was 14
943.18 Da and whole crotoxin presented two masses
of 23 643.36 Da and 24 284.74 Da, due to the
presence of two diﬀerent crotapotin isoforms.
3.5. Amino Acid Sequence Determination
The new crotoxin B isoform PLA2 F6a subunit
was reduced and carboxymethylated. It was then
subjected to analytical reverse-phase HPLC, and the
Fig. 1. (a) Elution proﬁle of Crotalus durissus collilineatus venom showing puriﬁcation of new crotoxin B isoform PLA2 F6a in a single
step, using a l-Bondapack C18 column. (b) Activity of PLA2s isolated from venoms of Crotalus durissus collilineatus (isoforms F6 and
F6a) venom. Buth isoform PLA2 (F6 and F6a) was incubated with crotapotins isoforms F3 and F4 for 30 min at 37 C, and the residual
PLA2 activity was then determined.
Fig. 2. (a) Amino acid composition of new crotoxin B isoform PLA2 F6a and isoforms of crotapotin (F3 and F4) of the complex crotox-
in. (b) Determination mass from crotapotin isoforms F3, F4, to new crotoxin B isoform PLA2 F6a and crotoxin by Mass Spectrometry
MALDI-tof.
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puriﬁed fraction was digested with SV8 and clostri-
pain. Digestion with SV8 and clostripain resulted in
nine and ten major peaks, respectively, in reverse-
phase HPLC. The new crotoxin B isoform PLA2
F6a revealed a sequence of 122 amino acids, with
approximately 90% homology with crotoxin B from
Crotalus durissus terriﬁcus and Mojave toxin,
although this similarity fell to around 70% when
compared with other venom PLA2s (Fig. 3). Cro-
toxin B showed high sequence identity with other
snake venom PLA2s in the Ca
2+ binding loop and
in the active site region (Fig. 3).
3.6. Eﬀects on the Mouse Phrenic Nerve-diaphragm
and Chick Biventer Cervicis Preparation
The eﬀect on neuromuscular preparation of
whole crotoxin and new crotoxin B isoform PLA2
F6a from Crotalus durissus collilineatus was studied
in mouse phrenic nerve-diaphragm and chick biven-
ter cervicis nerve-muscle preparations. When using
a concentration of 10 lg/ml, whole crotoxin af-
fected the neuro-muscular transmission in both sys-
tems tested (Fig. 4), with times to reach 50%
blockade of 82 min±1.12 min for mouse phrenic
nerve-diaphragm preparation and 19±0.98 min for
chick biventer cervicis preparation. For both prepa-
rations the blockade was irreversible. The crotoxin
or new crotoxin B isoform PLA2 (F6a), did not sig-
niﬁcantly blockade the ACh and KCl-induced con-
tractures when compared to the control values
(Fig. 4d). In the control preparations, the contrac-
ture to ACh and KCl kept stable, after a 120 min
indirect stimulation when compared to the control
values (data not shown).
In the case of the new crotoxin B isoform PLA2
F6a the results were diﬀerent depending on the
preparation used. Crotoxin B did not aﬀect neuro-
muscular transmission in mouse phrenic nerve-
diaphragm preparation, but induced a decrease in
twicht tension in the chick biventer cervicis prepara-
tion (Fig. 4b). Again, in the latter preparation, the
blockade was irreversible after washing. The average
time required to reach 50% blockade was crotoxin
22.75±1.11 and new crotoxin B isoform PLA2 F6a
42.61±1.35 min for chick biventer cervicis nerve-
muscle preparation (Fig. 3c). In control experiments,
the registration of the contractions was stable (92%
during 120 min) (Fig 4).
3.7. Cytotoxic Eﬀect on Myoblasts and Myotubes
In vitro, crotoxin was devoid of cytotoxicity
when tested against both C2C12 myoblasts and
Fig. 3. Amino acid sequence and molecular homology of new crotoxin B isoform PLA2 F6a from Crotalus durissus collilineatus with
other PLA2: PA2B_CROSS from Crotalus scutulatus scutulatus (Aird, S.D., et al., 1990) 91.8%; PA2B_CRODU from Crotalus durissus
terriﬁcus (Aird, S.D., et al., 1986) 91.8%; PA2C_CRODU from Crotalus durissus terriﬁcus (Faure, G., et al., 1994) 86.9%; PA23_
AGKHP from Agkistrodon halys Pallas (Kondo, K., et al., 1989) 73%; PA2A_TRIMU from Trimeresurus mucrosquamatus (Tsai, I.H.,
et al., 1995) 65.6%; PA2N_TRIFL from Trimeresurus ﬂavoviridis (Chijiwa, T., et al., 2003) 63.1%; PA21_BOTAS from Bothrops asper
(Kaiser, I.I., et al., 1990) 60.7% and PA21_BOTJR from Bothrops jararacussu (Moura-da-Silva, A.M., et al., 1995) 59%.
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myotubes, at doses up to 40 lg/well (265 lg/ml). At
this dose, new crotoxin B isoform PLA2 (F6a) was
able to lyse both types of cells, with a higher cyto-
toxic eﬀect towards myotubes than towards less
diﬀerentiated myoblasts (Fig. 5).
4. DISCUSSION
The puriﬁcation protocols used here were sim-
ple, quick, eﬃcient, and reproducible, yielding pure
crotapotin isoforms F3 and F4 and crotoxin B
Fig. 4. (a) Neurotoxic activity of crotoxin and new crotoxin B isoform PLA2 F6a in mouse phrenic nerve-diaphragm preparations, which
were allowed to stabilize for at least 20 min before the addition of a single dose (10 lg/ml) of each of the toxins followed by incubation
for 120 min (n = 5). (b) Neurotoxic activity of crotoxin and new crotoxin B isoform PLA2 F6a in the chick biventer cervicis preparation,
which were allowed to stabilize for at least 20 min before the addition of a single dose (10 lg/ml) of each of the crotoxin or new crotoxin
B isoform PLA2 F6a. (c) Eﬀect of blockage 50% of the crotoxin and new crotoxin B isoform PLA2 F6a from Crotalus durissus collilinea-
tus on muscle contractions induced and (d) Eﬀect of the crotoxin and new crotoxin B isoform PLA2 F6a from Crotalus durissus collilinea-
tus on the response of the chick biventer cervicis preparation to the acetylcholine (Ach 10 and 20 lg/ml) and potassium (KCl 13.4 mM)
after 120-min incubation. The preparation was exposed to the crotoxin and new crotoxin B isoform PLA2 F6a, in the concentration
10 mg/ml placed under each histogram. Each point represents the average of ﬁve experiments EPM per concentration p < 0.05 compared
to the corresponding control (Krebs solution alone) (Student t-test).
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PLA2 isoforms F6 and F6a from the venom of Cro-
talus durissus collilineatus. Thus, although crotapo-
tins isoforms F3 and F4 had similar chemical
properties, the two proteins diﬀerent in their ability
to inhibit of isoforms of PLA2 (F6 and F6a). This
ﬁnding suggests that these two crotapotins diﬀer in
their structure and that this diﬀerence is reﬂected in
their inhibitory activity. These conclusions agree
with work by (Faure and Bon, 1988) and (Ponce-
Soto, 2002).
The crotoxin has been described as the most
potent neurotoxic compound found to Crotalus
durissus terriﬁcus venom and this compound it is
composed by reversible association between a little
neurotoxic basic PLA2 and non neurotoxic and
acid compound (crotapotin) (Habermann and
Breithaupt, 1978; Faure and Bon, 1988). Thus
during years the neurotoxic eﬀect of crotalic PLA2
is mainly dependent of the presence of crotapotin.
But in this paper we showed that Crotalus durissus
collilineatus new crotoxin B isoform PLA2 (F6a)
induced a strong neurotoxic and cytotoxic eﬀect
independently the presence of crotapotin and this
eﬀect is strongly dependent of basic amino acid
residue located in the new crotoxin B isoform PLA2
F6a.
As expected, of new crotoxin B isoform PLA2
F6a from Crotalus durissus collilineatus shows high
sequence identity with crotoxin B from Crotalus
durissus terriﬁcus and with the PLA2 subunit of
Mojave toxin, from the North American rattlesnake
Crotalus scutulatus. Moreover, two diﬀerent crota-
potin variants were isolated. Heterogeneity in the
composition of crotapotins present in crotoxin
explains the existence of multiple crotoxin isoforms
in the venom of Crotalus durissus terriﬁcus (Faure
and Bon, 1987). It is therefore likely that a similar
phenomenon occurs in Crotalus durissus collilineatus.
The amino acid sequence of the new crotoxin B
isoform PLA2 F6a showed highly conserved basic
amino acid residues in the C-terminal domain,
which, according to some authors, is responsible for
heparin binding and membrane-destabilizing eﬀect
(Lomonte, 1994; Selistre de Arau´jo, 1996; Chioato,
2002). This region seems to be important in
accounting for the biological action and interaction
of these PLA2 with the cell membrane and the
presence of basic amino acid residues play an
important role for these activities (Gutie´rrez and
Lomonte, 1995; Lomonte, 2003).
Crotoxin from Crotalus durissus terriﬁcus has
been extensively characterized as a potent neuro-
toxic PLA2 complex which acts predominantly at
the presynaptic level in neuromuscular junctions
(Brazil and Excell, 1971; Hawgood and Smith,
1977), which contains basic phospholipase A2 and
an acidic protein, crotapotin (Rubsamen, 1971). We
assessed the ability of whole crotoxin and crotoxin
B to aﬀect neuro-muscular transmission in two
diﬀerent preparations.
When using mouse phrenic nerve-diaphragm
preparation, only whole crotoxin induce blockade,
whereas both crotoxin and new crotoxin B isoform
PLA2 F6a aﬀected chick biventer cervicis prepara-
tion. Thus, as previously demonstrated for crotoxin
isolated from Crotalus durissus terriﬁcus venom, the
isolated subunit B is able to exert neurotoxic eﬀects,
although its neurotoxicity is greatly enhanced by
the presence of crotapotin (Habermann and
Breithaupt, 1978; Bon, 1989).
Postsynaptically active neurotoxins would
block response to cholinoreceptors agonists. A
presynaptically active neurotoxin would abolish
nerve-evoked twitches, without aﬀecting response to
cholinoreceptor agonists. The fact that crotoxin
and the new crotoxin B isoform PLA2 F6a from
Fig. 5 In vitro membrane-damaging activities of Crotalus durissus
collilineatus crotoxin and new crotoxin B isoform PLA2 F6a.
Cytotoxic activity on murine C2C12 skeletal muscle myoblasts
and myotubes. Cell lysis was estimated by the release of lactic
dehydrogenase (LDH) to supernatants, after 3 h of exposure to
the toxin, in a volume of 150 ll/well. Each point represents the
mean±SD of triplicate cell cultures.
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Crotalus durissus collilineatus did not signiﬁcantly
aﬀect the responses to ACh and KCl added in the
preparation agrees with what is known about the
interference of the Crotalus durissus terriﬁcus venom
on ACh release (Hawgood and Smith, 1977;
Hawgood and Santana de Sa´, 1979).
Crotoxin is known to induce potent myotoxic-
ity in vivo, and the whole crotoxin complex is more
active at inducing muscle damage than isolated
crotoxin B (Gopalakrishnakone, 1984).
Pharmacologically, the whole crotoxin exercise
both pre- and post-synaptic actions, although the
crotapotin component is generally considered to be
pharmacologically inactive, serving merely as a
chaperon protein for the PLA2 and increasing its
biological activity (Breithaupt, 1976; Habermann
and Breithaupt, 1978; Bon, 1979). Although diﬀerent
subspecies of Crotalus durissus have been found to
present slight variation in the properties of their
PLA2, the crotapotins has been considered to be the
same. In the subspecies investigated here, however
(Crotalus durissus collilineatus) the new crotoxin B
isoform PLA2 F6a showed neurotoxic in the chick
biventer cervicis preparation and cytotoxic activities
independent the presence of crotapotin.
The Crotalus durissus collilineatus PLA2
showed conserved basic amino acid residues simi-
larly to found in the bothropic PLA2. This region
probably is involved in the neurotoxic activity of
this PLA2. Several studies made with other PLA2
also showed that C-terminal region play important
role for the neurotoxic eﬀect and the diﬀerence in
the amino acid sequences of this region has a evi-
dent relationship to neurotoxic potency (Krizaj,
1989; Curin-Serbec, 1991; Lomonte, 2003; Prijatelj,
2003). Thus these conserved basic amino acid resi-
dues seem to be involved in the neurotoxic eﬀect of
new crotoxin B isoform PLA2 F6a from the Crota-
lus durissus collilineatus but it is not the unique
region responsible for this eﬀect.
The new crotoxin B isoform PLA2 F6a exhibits
speciﬁc neurotoxic activity (as other D49 neurotoxic
PLA2), in the presence of acid subunits as seen in
the mouse phrenic nerve-diaphragm but also inde-
pendent of this subunit as seen in the chick biventer
cervicis preparation. In the agreement with our
results, we conclude that toxicity, neurotoxicity or
cytotoxicity of new crotoxin B isoform PLA2 (F6a)
is not dependent on the presence of other molecules
(as crotapotin) and probably involve other mecha-
nisms related with the speciﬁcity or bound likeness
to receivers.
Our present ﬁndings on a mouse muscle cell
line grown in culture evidence that whole crotoxin
lacks cytotoxicity on myoblasts and on diﬀerentiated
myotubes, whereas new crotoxin B isoform
PLA2 (F6a) aﬀects myotubes in the experimental
conditions of this study. It is suggested that the
myoblasts and myotubes utilized lack a speciﬁc high
aﬃnity receptor for crotoxin, thus explaining the
lack of eﬀect of whole crotoxin, since the complex
probably does not dissociate in these conditions. In
contrast, isolated new crotoxin B isoform PLA2
(F6a) is able to aﬀect myotubes, probably by
directly altering the integrity of the plasma mem-
brane of these multinucleated cells.
These ﬁndings agree with previous studies that
documented the higher toxicity of new crotoxin B
isoform PLA2 (F6a), when compared with whole
crotoxin, on myotubes in culture (Lomonte, 1999).
These results are in agreement with recent studies
demonstrating the higher susceptibility of myotubes
over myoblasts to the cytolytic eﬀect of several class
II PLA2s with myotoxic activity, but not to general
cytolytic agents (Angulo and Lomonte, 2002).
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